Blood cancers

CAR T-cell therapy indications to extend beyond r/r DLBCL

The rapidly evolving field of CAR T-cell therapy is likely to see indications extend to other lymphomas beyond diffuse large B-cell lymphoma (DLBCL), a leading haematologist says. There is also the prospect of CAR T-cell therapy being used earlier in the course of DLBCL, according to Dr Glen Kennedy, a haematologist and director of Cancer ...

Already a member?

Login to keep reading.

© 2021 the limbic